Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Cash from Operations: 2009-2024

Historic Cash from Operations for Tg Therapeutics (TGTX) over the last 16 years, with Dec 2024 value amounting to -$40.5 million.

  • Tg Therapeutics' Cash from Operations fell 89.70% to -$23.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$70.1 million, marking a year-over-year decrease of 149.49%. This contributed to the annual value of -$40.5 million for FY2024, which is 28.98% down from last year.
  • Tg Therapeutics' Cash from Operations amounted to -$40.5 million in FY2024, which was down 28.98% from -$31.4 million recorded in FY2023.
  • Tg Therapeutics' Cash from Operations' 5-year high stood at -$31.4 million during FY2023, with a 5-year trough of -$295.6 million in FY2021.
  • In the last 3 years, Tg Therapeutics' Cash from Operations had a median value of -$40.5 million in 2024 and averaged -$82.7 million.
  • As far as peak fluctuations go, Tg Therapeutics' Cash from Operations plummeted by 61.52% in 2020, and later spiked by 82.17% in 2023.
  • Over the past 5 years, Tg Therapeutics' Cash from Operations (Yearly) stood at -$214.5 million in 2020, then crashed by 37.82% to -$295.6 million in 2021, then skyrocketed by 40.41% to -$176.2 million in 2022, then surged by 82.17% to -$31.4 million in 2023, then declined by 28.98% to -$40.5 million in 2024.